Clinical Trials · NCT00113360
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 67
- Start date
- Jan 2005
- Locations
- 1 site, United States
- Primary endpoint
- Progression Free Survival (PFS)